Hoth Therapeutics Resumes At-the-Market Equity Offering Program

Hoth Therapeutics ( (HOTH) ) has shared an update.

Hoth Therapeutics, Inc. disclosed that it had previously suspended and terminated the prospectus supplement and related prospectus for issuing common stock under its November 8, 2024 At the Market Offering Agreement with H.C. Wainwright & Co., LLC, while keeping the underlying agreement itself in effect. On April 16, 2026, the company moved to resume securities sales under this arrangement by filing a new prospectus supplement to its Form S-3 registration statement, which had been declared effective by the SEC on December 4, 2025, supported by a legal opinion on the validity of the securities involved.

This step restores Hoth’s ability to raise capital through at-the-market issuances, potentially improving its financial flexibility for ongoing operations and development programs. The resumption of this capital-raising channel may influence the company’s funding strategy and could carry implications for existing shareholders as additional equity is sold into the market.

More about Hoth Therapeutics

Hoth Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutic solutions, with its operations funded in part through offerings of common stock in the public capital markets. The company utilizes at-the-market equity programs to provide flexible access to financing as it advances its corporate and clinical objectives.

Average Trading Volume: 2,734,625

Technical Sentiment Signal: Sell

Current Market Cap: $13.33M

Learn more about HOTH stock on TipRanks’ Stock Analysis page.